You searched for "oedema"
Outcomes of treat & extend ranibizumab in diabetic macular oedema
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...
Cystoid macular oedema following retinal detachment surgery
There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...
Steroid treatment for pseudophakic cystoid macular oedema
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...Diabetes macular oedema in pregnancy self-resolving postpartum
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...
Intravitreal dexamethasone implant for diabetic macular oedema
The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were...
Cystoid macular oedema following cataract surgery
This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...Management of diabetic macular oedema in vitrectomised eyes
Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....
A novel presentation of optic disc oedema with syphilis
Optic disc oedema (ODE) due to syphilis without visual compromise has been primarily attributed to papilloedema from raised intracranial pressure or optic perineuritis from optic nerve sheath inflammation. These terms were proposed before magnetic resonance imaging (MRI) was largely available....
Inner nuclear layer of the retina showing increase in thickness in diabetic macular oedema
Diabetic retinopathy is one of the leading causes of blindness in the developed world. With optical coherence tomography (OCT), it has become possible to image the retina in vivo and to measure retinal oedema by measuring retinal thickness (RT) with...
Ranibizumab versus laser in diabetic macular oedema (LUCIDATE study)
The aim of this study was to compare the functional and structural effects of Ranibizumab versus macular laser treatment in patients with diabetic macular oedema. It was a single centre, prospective, randomised, single masked clinical trial spanning a 48 week...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
